```
=> s l7
L8          17 L7

=> d his

     (FILE 'HOME' ENTERED AT 12:05:09 ON 15 JUN 2008)

     FILE 'REGISTRY' ENTERED AT 12:05:25 ON 15 JUN 2008
L1             STRUCTURE UPLOADED
L2              1 S L1
L3             18 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 12:06:15 ON 15 JUN 2008
L4             15 S L3

     FILE 'REGISTRY' ENTERED AT 12:11:04 ON 15 JUN 2008
L5             STRUCTURE UPLOADED
L6              4 S L5
L7            115 S L5 FUL

     FILE 'CAPLUS' ENTERED AT 12:11:48 ON 15 JUN 2008
L8             17 S L7

=> s l8 not l4
L9             2 L8 NOT L4

=> d abs fbib hitstr 1-2

L9   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AB    A method is presented for conveniently tritiating the aryl Me sulfones of
      compds. identified as potent and selective inhibitors of human Cox-2 and as DP
      receptor antagonists.  A base-catalyzed exchange reaction was conducted with
      deuterated water and the total deuterium incorporation, ranging from 46 to
      99%, was calculated using mass spectrometry.  Results from these exchanges
      were used as guidelines for tritium labeling giving specific radioactivities
      in the range of 28-120 mCi/mmol (1.03-4.43 GBq/mmol).
AN   2004:1040450  CAPLUS Full-text
DN   142:429673
TI   Base-catalyzed deuterium and tritium labeling of aryl methyl sulfones
AU   Scheigetz, John; Berthelette, Carl; Li, Chun; Zamboni, Robert J.
CS   Department of Medicinal Chemistry, Merck Frosst Centre for Therapeutic
     Research, Pointe-Claire/Dorval, QC, H9R 4P8, Can.
SO   Journal of Labelled Compounds & Radiopharmaceuticals (2004), 47(12),
     881-889
     CODEN: JLCRD4; ISSN: 0362-4803
PB   John Wiley & Sons Ltd.
DT   Journal
LA   English
OS   CASREACT 142:429673
IT   850896-74-1
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (base-catalyzed deuterium and tritium labeling of aryl Me sulfones)
RN   850896-74-1  CAPLUS
CN   1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-
     dihydro-8-(methylsulfonyl)-6-(2-methyl-2H-tetrazol-5-yl)-, (1R)-  (CA
     INDEX NAME)

Absolute stereochemistry.
```



IT 850896-74-1DP, tritiated 850896-79-6P
850896-80-9P 850896-81-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(base-catalyzed deuterium and tritium labeling of aryl Me sulfones)
RN 850896-74-1 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(methylsulfonyl)-6-(2-methyl-2H-tetrazol-5-yl)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 850896-79-6 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(methyl-d-sulfonyl)-6-(2-methyl-2H-tetrazol-5-yl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850896-80-9 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(methyl-d2-sulfonyl)-6-(2-methyl-2H-tetrazol-5-yl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850896-81-0 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(methyl-d3-sulfonyl)-6-(2-methyl-2H-tetrazol-5-yl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I II

AB Title compds. I [wherein R1, R2, and R3 = independently H, halo, CN, CORa, CO2Ra, CONRaRb, OCONRaRb, SO0-2-(hetero)aryl, NRaSO0-2Rb, NRaRb, NRaCORb, NRaCO2Rb, NRaCONRaRb, SO0-2NRaRb, NO2, cycloalkenyl, or (un)substituted alkyl, alkenyl, alkoxy, heterocyclyl, (hetero)aryl(oxy), or SO0-2-alkyl; Ra and Rb =

independently H or (un)substituted alkyl, alkenyl, alkynyl, heterocyclyl, or (hetero)aryl; or NRaRb = heterocyclyl; R4 = H, CN, (halo)alkyl, ORa, or SO0-2-alkyl; R5 = H or (halo)alkyl; or CR4R5 = (un)substituted 3- or 4-membered (hetero)cycloalkyl; R6 = H or (un)substituted alkyl; Ar = (un)substituted (hetero)aryl; A = (un)substituted alkyl; Q = CO2H, CONRaRb, CONHSO2Rc, SO2NHRa, SO2NHRa, SO3H, PO3H2, or tetrazolyl; Rc = (un)substituted alkyl; Y1 = (un)substituted alkylidene optionally interrupted by O, S, NRa, CO, OCO, etc.; Y2 = (un)substituted methylene, ethylene, or ethenylene; and pharmaceutically acceptable salts and hydrates thereof] were prepared as non-steroidal D2 prostaglandin receptor antagonists (no data). For example, 4-[2-bromo-3-(4-chlorobenzyl)-1H-1-indolyl]butanal (4-step preparation given) was coupled with (carbethoxymethylene)triphenylphosphorane to give the Et (E)-2-hexenoate. Cyclization using Bu4NCl, TEA, and Pd(AcO)2 in DMF afforded Et 2-[10-(4-chlorobenzyl)-6,7,8,9-tetrahydropyrido[1,2- a]indol-9-yliden]acetate. Reduction with Pd/C (5%, weight/weight) followed by saponification with LiOH in MeOH provided II. I are useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion, and asthma (no data).

AN 2002:906233 CAPLUS Full-text

DN 138:4518

TI Preparation of dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]indole derivatives as prostaglandin D2 receptor antagonists for treatment of allergic rhinitis, nasal congestion, and asthma

IN Wang, Zhaoyin; Dufresne, Claude; Guay, Daniel; Leblanc, Yves

PA Merck Frosst Canada & Co., Can.; Beaulieu, Christian

SO PCT Int. Appl., 225 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002094830	A2	20021128	WO 2002-CA745		20020522
	WO 2002094830	A3	20030306			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-293077P	P	20010523
	CA 2447779	A1	20021128	CA 2002-2447779		20020522
				US 2001-293077P	P	20010523
				WO 2002-CA745	W	20020522
	AU 2002302248	A1	20021203	AU 2002-302248		20020522
	AU 2002302248	B2	20080306			
				US 2001-293077P	P	20010523
				WO 2002-CA745	W	20020522
	EP 1395590	A2	20040310	EP 2002-729708		20020522
	EP 1395590	B1	20060927			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-293077P	P	20010523
				WO 2002-CA745	W	20020522
	JP 2004534774	T	20041118	JP 2002-591503		20020522
				US 2001-293077P	P	20010523
				WO 2002-CA745	W	20020522

AT 340796	T	20061015	AT 2002-729708		20020522
			US 2001-293077P	P	20010523
ES 2272712	T3	20070501	ES 2002-729708		20020522
			US 2001-293077P	P	20010523
US 20040180934	A1	20040916	US 2003-474929		20031015
US 7144913	B2	20061205			
			US 2001-293077P	P	20010523
			WO 2002-CA745	W	20020522

OS MARPAT 138:4518

IT 476618-26-5P, Methyl [8-acetyl-9-[(4-chlorophenyl)sulfanyl]-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-32-3P, Methyl [9-[(4-chlorophenyl)sulfanyl]-6-fluoro-8-(1-methoxyethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-37-8P, Methyl [8-acetyl-6-fluoro-9-(phenylsulfanyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-39-0P, Methyl [8-acetyl-9-[(3,4-dichlorophenyl)sulfanyl]-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-41-4P, Methyl [9-[(4-chlorophenyl)sulfanyl]-6-fluoro-8-(2,2,2-trifluoro-1-methoxyethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-44-7P, Methyl [9-[(4-chlorophenyl)sulfanyl]-6-fluoro-8-(1-methoxypropyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-52-7P, Methyl [9-[(4-chlorophenyl)sulfanyl]-6-methoxy-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-61-8P, Methyl [9-[(4-chlorophenyl)thio]-8-isopropyl-6-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-64-1P, Methyl [9-[(4-chlorophenyl)thio]-6-isopropoxy-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-70-9P, Methyl [6-(benzyloxy)-9-[(4-chlorophenyl)thio]-8-isopropyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-74-3P, Methyl [9-[(4-chlorophenyl)thio]-8-(methylsulfonyl)-6-[[(trifluoromethyl)sulfonyl]oxy]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476618-75-4P, Methyl [6-(4-chlorophenyl)-9-[(4-chlorophenyl)thio]-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476619-03-1P, Methyl [9-[(4-chlorophenyl)thio]-6-fluoro-8-(1-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476619-72-4P, Ethyl [9-[(4-chlorophenyl)thio]-6-fluoro-8-(methylsulfonyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476620-46-9P, Methyl [9-[(4-chlorophenyl)thio]-8-isopropyl-6-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476620-57-2P, Methyl [9-[(4-chlorophenyl)thio]-5,6-difluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476620-59-4P, Methyl [8,9-bis[(4-chlorophenyl)thio]-5,6-difluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476620-60-7P, Methyl [9-[(4-chlorophenyl)thio]-6-fluoro-5,8-bis(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate 476620-64-1P, Methyl [9-[(4-chlorophenyl)thio]-6-methoxy-5,8-bis(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrroloindole and pyridoindole prostaglandin D2 receptor antagonists by cyclization of (indolyl)alkanoates and (indolyl)alkenoates)

RN 476618-26-5 CAPLUS

CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 8-acetyl-9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-, methyl ester (CA INDEX NAME)



RN 476618-32-3 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(1-methoxyethyl)-, methyl ester (CA INDEX NAME)



RN 476618-37-8 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 8-acetyl-6-fluoro-2,3-dihydro-9-(phenylthio)-, methyl ester (CA INDEX NAME)



RN 476618-39-0 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 8-acetyl-9-[(3,4-dichlorophenyl)thio]-6-fluoro-2,3-dihydro-, methyl ester (CA INDEX NAME)



RN 476618-41-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(2,2,2-trifluoro-1-methoxyethyl)-, methyl ester (CA INDEX NAME)



RN 476618-44-7 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(1-methoxypropyl)-, methyl ester (CA INDEX NAME)



RN 476618-52-7 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-6-methoxy-8-(methylsulfonyl)-, methyl ester (CA INDEX NAME)



RN 476618-61-8 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(1-methylethyl)-6-(methylsulfonyl)-, methyl ester (CA INDEX NAME)



RN 476618-64-1 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-6-(1-methylethoxy)-8-(methylsulfonyl)-, methyl ester (CA INDEX NAME)



RN 476618-70-9 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(1-methylethyl)-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 476618-74-3 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(methylsulfonyl)-6-[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester (CA INDEX NAME)



RN 476618-75-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 6-(4-chlorophenyl)-9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(methylsulfonyl)-, methyl ester (CA INDEX NAME)



RN 476619-03-1 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(1-hydroxyethyl)-, methyl ester (CA INDEX NAME)



RN 476619-72-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(methylsulfonyl)-3-oxo-, ethyl ester (CA INDEX NAME)



RN 476620-46-9 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(1-methylethyl)-6-(2-methyl-2H-tetrazol-5-yl)-, methyl ester (CA INDEX NAME)



RN 476620-57-2 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-5,6-difluoro-2,3-dihydro-8-(methylsulfonyl)-, methyl ester (CA INDEX NAME)



RN 476620-59-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 8,9-bis[(4-chlorophenyl)thio]-5,6-difluoro-2,3-dihydro-, methyl ester (CA INDEX NAME)



RN 476620-60-7 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-5,8-bis(methylsulfonyl)-, methyl ester (CA INDEX NAME)



RN 476620-64-1 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-6-methoxy-5,8-bis(methylsulfonyl)-, methyl ester (CA INDEX NAME)



IT 476620-47-0P, Methyl [9-[(4-chlorophenyl)thio]-8-isopropyl-6-(1-methyl-1H-tetrazol-5-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrroloindole and pyridoindole prostaglandin D2 receptor antagonists by cyclization of (indolyl)alkanoates and (indolyl)alkenoates)

RN 476620-47-0 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-2,3-dihydro-8-(1-methylethyl)-6-(1-methyl-1H-tetrazol-5-yl)-, methyl ester (CA INDEX NAME)



IT 476618-92-5P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(prostaglandin D2 receptor antagonist; preparation of pyrroloindole and pyridoindole prostaglandin D2 receptor antagonists by cyclization of (indolyl)alkanoates and (indolyl)alkenoates)

RN 476618-92-5 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(methylsulfonyl)- (CA INDEX NAME)



IT 476618-95-8P, [(1R)-9-[(4-Chlorophenyl)thio]-6-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prostaglandin D2 receptor antagonist; preparation of pyrroloindole and pyridoindole prostaglandin D2 receptor antagonists by cyclization of (indolyl)alkanoates and (indolyl)alkenoates)

RN 476618-95-8 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(methylsulfonyl)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 476618-27-6P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(trifluoroacetyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
476618-28-7P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-30-1P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(1-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
476618-42-5P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(1-hydroxypropyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
476620-44-7P, [9-[(4-Chlorophenyl)thio]-6-cyano-8-isopropyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prostaglandin D2 receptor antagonist; preparation of pyrroloindole and pyridoindole prostaglandin D2 receptor antagonists by cyclization of (indolyl)alkanoates and (indolyl)alkenoates)

RN 476618-27-6 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(2,2,2-trifluoroacetyl)- (CA INDEX NAME)



RN 476618-28-7 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(2,2,2-trifluoro-1-hydroxyethyl)- (CA INDEX NAME)



RN 476618-30-1 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(1-hydroxyethyl)- (CA INDEX NAME)



RN 476618-42-5 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(1-hydroxypropyl)- (CA INDEX NAME)



RN 476620-44-7 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-cyano-2,3-dihydro-8-(1-methylethyl)- (CA INDEX NAME)



IT 476618-25-4P, [8-Acetyl-9-[(4-chlorophenyl)sulfanyl]-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-29-8P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(1-hydroxy-2-methylpropyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-31-2P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(1-methoxyethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-33-4P 476618-34-5P 476618-35-6P, [8-Acetyl-6-fluoro-9-(phenylsulfanyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-38-9P, [8-Acetyl-9-[(3,4-dichlorophenyl)sulfanyl]-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-40-3P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(2,2,2-trifluoro-1-methoxyethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-43-6P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-(1-methoxypropyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-45-8P, [9-[(4-Chlorophenyl)sulfanyl]-6-fluoro-8-[1-(methylsulfanyl)ethyl]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-46-9P, [9-[(4-Chlorophenyl)sulfanyl]-6-methoxy-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-53-8P, [6-(Benzyloxy)-9-[(4-chlorophenyl)sulfanyl]-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-56-1P, [9-[(4-Chlorophenyl)thio]-8-(methylsulfonyl)-6-(methylthio)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-57-2P, [9-[(4-Chlorophenyl)thio]-8-isopropyl-6-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-62-9P, [9-[(4-Chlorophenyl)thio]-6-isopropoxy-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-65-2P, [6-(Benzyloxy)-9-[(4-chlorophenyl)thio]-8-isopropyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-71-0P, [9-[(4-Chlorophenyl)thio]-8-isopropyl-6-methoxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-72-1P, [6-(4-Chlorophenyl)-9-[(4-chlorophenyl)thio]-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-85-6P, [8-Acetyl-9-[(4-chlorophenyl)thio]-6-cyano-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-86-7P, [8-Acetyl-9-[(4-chlorophenyl)thio]-6-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476618-96-9P, [9-[(4-Chlorophenyl)thio]-8-(ethylsulfonyl)-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-01-9P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-propyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-02-0P, [9-[(4-Chlorophenyl)thio]-8-ethyl-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-04-2P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-isopropenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-06-4P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-isopropyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-09-7P, [(1R)-9-[(4-Chlorophenyl)thio]-6-fluoro-8-isopropyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-13-3P, [9-[(4-Chlorophenyl)thio]-8-(1-

ethylprop-1-enyl)-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-14-4P, [9-[(4-Chlorophenyl)thio]-8-(1-ethylpropyl)-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-24-6P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-vinyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-26-8P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-44-0P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-59-7P, [6-Fluoro-8-(methylsulfonyl)-9-[(2,4,5-trichlorophenyl)thio]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-65-5P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-(methylsulfonyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-86-0P, [(1R)-6-Fluoro-8-(methylsulfonyl)-9-[[4-(trifluoromethyl)phenyl]thio]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-88-2P, [(1R)-6-Fluoro-8-(methylsulfonyl)-9-[[4-(methylsulfonyl)phenyl]thio]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-93-9P, [9-(1,3-Benzothiazol-2-ylthio)-6-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476619-95-1P, [9-[(4-Chlorophenyl)thio]-8-(methylsulfonyl)-6-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-02-7P , [6-Fluoro-8-isopropyl-9-(1-naphthylthio)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-03-8P, [6-Fluoro-8-isopropyl-9-(2-naphthylthio)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-05-0P, [6-Fluoro-8-(methylsulfonyl)-9-(pyrimidin-2-ylthio)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-09-4P, [9-[(4-Chlorophenyl)thio]-8-(1-methoxypropyl)-6-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-11-8P, [6-Fluoro-8-(methylsulfonyl)-9-(2-naphthylthio)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-12-9P, [9-[(4-Chloro-2-fluorophenyl)thio]-6-fluoro-8-isopropyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-13-0P, [9-[(4-Chloro-2-fluorophenyl)thio]-6-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-28-7P, [9-[(4-Chlorophenyl)thio]-8-cyano-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-45-8P, [9-[(4-Chlorophenyl)thio]-8-isopropyl-6-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-48-1P, [9-[(4-Chlorophenyl)thio]-8-isopropyl-6-(1-methyl-1H-tetrazol-5-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-49-2P, [9-[(4-Chlorophenyl)thio]-6,8-bis(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-56-1P, [9-[(4-Chlorophenyl)thio]-5,6-difluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-61-8P, [8,9-Bis[(4-chlorophenyl)thio]-5,6-difluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-62-9P, [9-[(4-Chlorophenyl)thio]-6-fluoro-5,8-bis(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-63-0P, [9-[(4-Chlorophenyl)thio]-6-methoxy-5,8-bis(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-65-2P, [9-[(4-Chlorophenyl)thio]-5-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-68-5P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]difluoroacetic acid 476620-82-3P 476620-91-4P, [9-[(4-(Trifluoromethyl)phenyl)thio]-6-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid 476620-92-5P, [9-[(4-(Methylsulfonyl)phenyl)thio]-6-fluoro-8-(methylsulfonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prostaglandin D2 receptor antagonist; preparation of pyrroloindole and pyridoindole prostaglandin D2 receptor antagonists by cyclization of (indolyl)alkanoates and (indolyl)alkenoates)

RN 476618-25-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 8-acetyl-9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro- (CA INDEX NAME)



RN 476618-29-8 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(1-hydroxy-2-methylpropyl)- (CA INDEX NAME)



RN 476618-31-2 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-(1-methoxyethyl)- (CA INDEX NAME)



RN 476618-33-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-

2,3-dihydro-8-[(1S)-1-methoxyethyl]-, (1R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 476618-34-5 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-[(1R)-1-methoxyethyl]-, (1R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 476618-35-6 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 8-acetyl-6-fluoro-2,3-dihydro-9-(phenylthio)- (CA INDEX NAME)



RN 476618-38-9 CAPLUS
CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 8-acetyl-9-[(3,4-dichlorophenyl)thio]-6-fluoro-2,3-dihydro- (CA INDEX NAME)


Cl
Cl
Ac
S
CH2—CO2H
F
N